DiamiR to Present at the GTCbio Biomarker Summit 2017
March 20, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 20, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira...
Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy
February 24, 2017 14:24 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the...
Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
October 06, 2016 07:00 ET
|
Summit Therapeutics PLC
Summit reports on development of new, automated biomarker tools to evaluate disease status of muscle biopsies OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
New Potential Lung Cancer Biomarkers Identified
April 19, 2016 08:00 ET
|
Protea Biosciences, Inc.
NEW ORLEANS, April 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of...
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
March 15, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November 09, 2015 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...
$1.5M Phase II SBIR Awarded to Expand Nanobind DNA/RNA Extraction Technology
October 07, 2015 09:17 ET
|
Circulomics
BALTIMORE, MD--(Marketwired - October 07, 2015) - Circulomics has been awarded a $1.5M Phase II SBIR grant by the National Institutes of Health (NIH)/National Institute of General Medical Sciences...
Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts
September 29, 2015 15:52 ET
|
Provista Diagnostics, Inc.
NEW YORK, NY, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel...
Circulomics Awarded $1.5M Phase II SBIR to Develop Multiplex microRNA Assay
May 13, 2015 09:17 ET
|
Circulomics
BALTIMORE, MD--(Marketwired - May 13, 2015) - Circulomics Inc has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) - National...
Circulomics Awarded Phase I SBIR to Develop Nanobind DNA Extraction Technology
April 30, 2014 10:12 ET
|
Circulomics
BALTIMORE, MD--(Marketwired - April 30, 2014) -
Circulomics Inc has been awarded a Phase I Small Business Innovative Research (SBIR) grant by the National...